CBD

Stay Ahead of Trends in Dietary Supplements

September 07, 2020

What supplements are patients looking for the most, and how can pharmacists help?

FDA Approves CBD Treatment for Seizures in Rare Genetic Disease

August 04, 2020

The FDA approved a cannabidiol oral solution treatment (Epidiolex, Greenwich Biosciences) for seizures associated with tuberous sclerosis complex.

Cannabis Series: FDA Support, Research in the Works

July 31, 2020

Our first episode of our latest Cannabis Series is focused on the burgeoning medical marijuana landscape, featuring FDA's guidelines and research on the diverse benefits of cannabis as medicine.

FDA Releases Guidance To Boost Cannabis Clinical Research

July 27, 2020

Responding to growing interest by industry stakeholders, the agency has offered draft guidance outlining quality considerations and other practical recommendations for cannabis and cannabis-derived compounds.

Systematic Review Evaluates Cannabis, Cannabinoids in Palliative and Supportive Oncology Care

May 30, 2020

A systematic review of medical cannabis and cannabinoid use in oncology care demonstrated varied results.

DEA Deschedules Antiepileptic CBD Oral Solution Epidiolex

April 07, 2020

Cannabidiol oral solution (Epidiolex, GW Pharmaceuticals) is no longer considered a controlled substance.

6 Ways to Diversify Your Pharmacy's Revenue Streams

March 06, 2020

Strategies for seizing revenue opportunities outside of the PBM.

Epidiolex sNDA Seeking FDA Approval for Tuberous Sclerosis Complex Indication

February 04, 2020

A supplemental application for cannabidiol oral solution (Epidiolex, GW Pharmaceuticals and Greenwich Biosciences) has been submitted for the treatment of seizures associated with tuberous sclerosis complex.